Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) Meeting Abstract
| Authors: | Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Nam, K.; Frenkl, T. L.; Godwin, J. L.; Bajorin, D. F.; Vaughn, D. J. |
| Abstract Title: | Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | v366 |
| End Page: | v367 |
| Language: | English |
| ACCESSION: | WOS:000491295502346 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz249.018 |
| Notes: | Meeting Abstract: 919P -- Source: Wos |
